Page last updated: 2024-09-04

cox 189 and Gastric Ulcer

cox 189 has been researched along with Gastric Ulcer in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Campos, ML; Chelucci, R; Chiquetto, R; Chung, MC; dos Santos, JL; Peccinini, RG	1
Barbieri, KP; Bosquesi, PL; Campos, ML; Chelucci, RC; Chin, CM; de Castro Souto, PC; Matsubara, MH; Moreira, V; Peccinini, RG; Santos, JL; Teixeira, C	1
Summerton, N	1
Doggrell, SA	1
Gitton, X; Hawkey, CJ; Krammer, G; Matchaba, P; Mellein, B; Richard, D; Sallstig, P; Smalley, W; Stricker, K; Weinstein, WM	1

Reviews

1 review(s) available for cox 189 and Gastric Ulcer

Article	Year
The safety of lumiracoxib when used in the treatment of arthritis. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:2 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Organic Chemicals; Stomach Ulcer	2005

Trials

1 trial(s) available for cox 189 and Gastric Ulcer

Article	Year
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology, 2007, Volume: 133, Issue:1 Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Duodenal Ulcer; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Risk Factors; Risk Reduction Behavior; Stomach Ulcer	2007

Article

Year

Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.

Gastroenterology, 2007, Volume: 133, Issue:1

Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Duodenal Ulcer; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Risk Factors; Risk Reduction Behavior; Stomach Ulcer

2007

Other Studies

3 other study(ies) available for cox 189 and Gastric Ulcer

Article	Year
Synthesis, characterization and pharmacological evaluation of 1-(2-chloro-6-fluorophenyl)-5-methylindolin-2-one: a new anti-inflammatory compound with reduced gastric ulceration properties. Molecules (Basel, Switzerland), 2010, Nov-08, Volume: 15, Issue:11 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cell Movement; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Stability; Female; Gastric Mucosa; Hydrogen-Ion Concentration; Indoles; Indomethacin; Lactams; Male; Mice; Prodrugs; Rats; Rats, Wistar; Stomach Ulcer	2010
Pharmacological evaluation and preliminary pharmacokinetics studies of a new diclofenac prodrug without gastric ulceration effect. International journal of molecular sciences, 2012, Nov-19, Volume: 13, Issue:11 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2; Diclofenac; Dinoprostone; Disease Models, Animal; Edema; Leukocytes; Male; Mice; Molecular Structure; Peritoneal Cavity; Prodrugs; Rats; Stomach Ulcer	2012
Evidence in practice--number 3: Cox 2 inhibitors. The British journal of general practice : the journal of the Royal College of General Practitioners, 2004, Volume: 54, Issue:508 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Evidence-Based Medicine; Humans; Ibuprofen; Middle Aged; Naproxen; Organic Chemicals; Osteoarthritis; Stomach Ulcer	2004